• About Us
  • Add Post
  • Contact
  • Contribute For Us
  • Homepage
  • Our Authors
  • Privacy Policy
What's Hot

Nikola Announces Pricing of $100.0 Million Common Stock Transactions

March 31, 2023

Ecopetrol comments on information published in the media

March 31, 2023

Rising Demand for Cloud-based Security Services Bolsters Growth

March 31, 2023
What's Hot

Nikola Announces Pricing of $100.0 Million Common Stock Transactions

March 31, 2023

Ecopetrol comments on information published in the media

March 31, 2023

Rising Demand for Cloud-based Security Services Bolsters Growth

March 31, 2023
Facebook Twitter Instagram
  • About Us
  • Contact
  • Add Post
  • Contribute For Us
  • Privacy Policy
  • Our Authors
Facebook Twitter LinkedIn
BusinessLendBusinessLend
  • NEWS
  • BUSINESS
  • AUTO
  • TECH
  • MONEY
  • STARTUP
  • SUCCESS STORIES
  • OTHER
    • Press Release
    • OPINION
Subscribe
BusinessLendBusinessLend
Home»Press Release»The global custom antibody market size is projected to reach USD 860 million by 2028 from USD 548 million in 2023, at a CAGR of 9.4%
Press Release

The global custom antibody market size is projected to reach USD 860 million by 2028 from USD 548 million in 2023, at a CAGR of 9.4%

PR NewsWireBy PR NewsWireMarch 13, 2023No Comments4 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

NEW YORK, March 13, 2023 /PRNewswire/ — The global custom antibody market size is projected to reach USD 860 million by 2028 from USD 548 million in 2023, at a CAGR of 9.4% during the forecast period. Factors such as increasing investment for the development of ADCs and rising research in structure-based drug design and therapeutics mAbs of custom antibody, are driving the market growth at a faster pace.

Read the full report: https://www.reportlinker.com/p05676490/?utm_source=PRN

Source: ReportLinker
Source: ReportLinker

The recombinant antibodies segment is likely to grow at highest CAGR during the forecast period of 2023-2028.

On the basis of type, the custom antibody market is segmented into monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and others.The recombinant antibodies segment is projected to grow at the highest CAGR during the forecast period.

The growth is attributed to low immunogenicity and increased research reproducibility offered by recombinant antibodies. This is likely to have a positive impact on segmental growth.

The mice source is expected to hold a dominant share in 2023.

Based on the source, the market is segmented into mice, rabbits, and others. The mice segment is expected to grow at a faster pace during the forecast period due to factors that mice are conventionally preferred hosts for mAbs production for research purposes.

In 2022, the research applications segment held a dominant share.

Based on application, the custom antibody market is segmented into research and therapeutic applications. The research applications segment held a dominant share of the custom antibody market. Adoption of custom antibody in research and drug discovery & development is one of the major factors anticipated to project the market growth

The oncology segment is likely to grow at highest CAGR during the forecast period of 2023-2028.

Based on indication, the custom antibody market is segmented into oncology, infectious diseases, immunology, neurobiology, cardiovascular diseases, and others.The oncology indication segment held a dominant share of the custom antibody market, in 2022.

The growing use of mAbs and custom antibody in cancer treatment is one of the major factor anticipated to project market growth.

Asia Pacific region is likely to grow at faster pace.

The custom antibody market is divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.In 2022, North America accounted for the dominant share of custom antibody market.

The dominance of the region is attributable to various factors such as the presence of dominant and key market players in the region coupled with the ongoing research activities of custom antibody. Asia Pacific region is likely to grow at a faster pace owing to various factors such as the growing awareness of personalized therapeutics, rising research initiatives undertaken by the government for antibody development in the region, and the emergence of new market players in the custom antibody market.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 60%, and Demand Side – 40%
  • By Designation (Supply Side): Managers – 45%, CXOs & Directors – 25%, Executives- 15%, Other -15.0%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%

Lists of Companies Profiled in the Report:

  • Thermo Fisher Scientific (US)
  • GenScript (China)
  • Abcam plc. (UK)
  • Cell Signaling Technology, Inc (US)
  • Bio-Rad Laboratories, Inc (US)
  • Merck KGaA (Germany)
  • Agilent Technologies, Inc (Germany)
  • PerkinElmer, Inc (US)
  • Rockland Immunochemicals, Inc (US)
  • ProMab Biotechnologies, Inc (US)
  • Innovagen AB (Sweden)
  • OriGene Technologies (US)
  • Bio-Techne (US)
  • Creative Diagnostics (US)
  • Sino Biological, Inc (China)
  • RayBiotech Life, Inc (US)
  • Abbiotec, Inc (US)
  • ProSci (US)
  • Boster Biological Technology (US)
  • CUSABIO Technology LLC (US)
  • Biointron (China)
  • Kaneka Eurogentech S.A. (Belgium)
  • Creative Biolabs (US)
  • Envigo (US)
  • Imgenex India Pvt. Ltd (India).

Research Coverage:

This report provides a detailed picture of the custom antibody market.It aims at estimating the size and future growth potential of the market across different segments, such as service, type, source, application, indication, end user, and region.

The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall custom antibody market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.

This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

Read the full report: https://www.reportlinker.com/p05676490/?utm_source=PRN

About Reportlinker

ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

Contact Clare: [email protected]

US: (339)-368-6001

Intl: +1 339-368-6001

SOURCE Reportlinker

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
PR NewsWire

PR Newswire is a distributor of press releases headquartered in Chicago. The service was created in 1954 to allow companies to electronically send press releases to news organizations, using teleprinters at first. The founder, Herbert Muschel, operated the service from his house in Manhattan for approximately 15 years.

Related Posts

Nikola Announces Pricing of $100.0 Million Common Stock Transactions

March 31, 2023

Ecopetrol comments on information published in the media

March 31, 2023
Add A Comment

Comments are closed.

Advertisement
Editors Picks

Co-op enlargement between Azerbaijan and Serbia mentioned (PHOTO)

November 22, 2022

Investigation of Zynex, Inc. (ZYXI) Announced by Holzer &

March 8, 2023

T-Mobile outage hits customers throughout the U.S.

February 14, 2023

The reinvention of Goldman Sachs: what has David Solomon achieved?

August 17, 2022
Advertisement
Latest Posts

Nikola Announces Pricing of $100.0 Million Common Stock Transactions

March 31, 2023

Ecopetrol comments on information published in the media

March 31, 2023

Rising Demand for Cloud-based Security Services Bolsters Growth

March 31, 2023

Business Lend is a platform which brings executives officers, entrepreneurs, and venture capitalist together from different sectors. We keep on connecting with our users with the help of our monthly edition carving our way slowly towards the highest readership.

Facebook Twitter Instagram LinkedIn
Must Read
  • Nikola Announces Pricing of $100.0 Million Common Stock Transactions March 31, 2023
  • Ecopetrol comments on information published in the media March 31, 2023
  • Rising Demand for Cloud-based Security Services Bolsters Growth March 31, 2023

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

© 2023 BusinessLend. Designed by ThemeSphere.
  • About Us
  • Contact
  • Add Post
  • Contribute For Us
  • Privacy Policy
  • Our Authors

Type above and press Enter to search. Press Esc to cancel.